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Background: Prescribed Minimum Benefits is a list of conditions that all medical schemes need 
to cover in full, and includes a select of chronic conditions. Chronic conditions affect people’s 
lifestyles and require ongoing management over a period of years for long-term survival.
Objectives:  This  study  examined  the  association  between  prevalence  of  selected  chronic 
diseases and health service use, in particular visits to general practitioners (GPs) by medical 
scheme members. 
Method: This was a retrospective study on medical schemes data. The median imputation 
method was employed to deal with missing and unreported chronic diseases prevalence. 
Multivariate logistic regression analysis was employed to assess effects of chronic disease 
prevalence, age stratum and scheme size on GP visits per annum. 
Results: The study showed that prevalence of asthma was significantly associated with more 
than three GP visits (OR = 1.081; 95% CI = 1.008–1.159), as was prevalence of type 2 diabetes 
(OR = 1.087; 95% CI = 1.027–1.152), whilst prevalence of hyperlipidaemia (OR = 0.92; 95% 
CI = 0.875–0.97) was more likely to be associated with less than three GP visits. Prevalence 
of hypertension was associated with more than three GP visits per year (OR = 1.132; 95% 
CI = 1.017–1.26).
Conclusion: This study shows that scheme size, prevalence of chronic diseases such as asthma, 
type 2 diabetes, hyperlipidaemia and hypertension are related to GP visits. GPs and managed 
care programmes employed by schemes should give special attention to certain disease states 
with high prevalence rates in an effort to better manage them. 
© 2012. The Authors.
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Les visites chez les médecins généralistes comme indicateur de l’accès à la prise en charge 
des maladies chroniques des membres des régimes d’assurance maladie, Afrique du Sud
Contexte: Les prestations minimums prescrites sont une liste de maladies que tous les régimes 
d’assurance  maladie  doivent  totalement  prendre  en  charge,  notamment  une  sélection  de 
maladies chroniques. Les maladies chroniques affectent  le mode de vie des personnes et 
nécessitent un suivi permanent pendant des années pour une survie à long terme.
Objectifs:  Cette  étude  examine  l’association  entre  la  prévalence  des  maladies  chroniques 
et  l’utilisation  des  services  de  santé,  en  particulier  les  consultations  chez  des  médecins 
généralistes par les membres des régimes d’assurance maladie.
Méthodes: Il s’agissait d’une étude rétrospective sur les données des régimes d’assurance 
maladie. La méthode d’imputation médiane a été utilisée pour traiter la prévalence des maladies 
chroniques manquantes et non déclarées. L’analyse de régression logistique multivariée a été 
utilisée pour évaluer les effets de la prévalence des maladies chroniques, les tranches d’âge et 
le nombre de consultations chez des médecins généralistes par an.
Résultats: L’étude montre que la prévalence de l’asthme était significativement associée à plus 
de trois consultations chez le médecin généraliste (OR = 1.081; 95% CI = 1.008–1.159), de même 
que la prévalence du diabète de type 2 (OR = 1.087; 95% CI = 1.027–1.152), alors que la prévalence 
de l’hyperlipidémie (OR = 0.92; 95% CI = 0.875–0.97) était plus susceptible d’être associée à 
moins de trois consultations chez le médecin généraliste. La prévalence de l’hypertension était 
associée à plus de trois consultations chez le médecin généraliste par an (OR = 1.132; 95% 
CI = 1.017–1.26).
Conclusion: Cette étude montre que la taille du régime d’assurance maladie et la prévalence de 
maladies chroniques telles que l’asthme, le diabète de type 2, l’hyperlipidémie et l’hypertension 
sont  liées  aux  consultations  chez  le  médecin généraliste.  Les  médecins généralistes  et  les 
programmes de soins utilisés par les régimes d’assurance maladie devraient accorder une 
attention particulière à certaines maladies présentant un taux de prévalence élevé afin de 
mieux les prendre en charge.
Introduction 
General practitioners’ (GPs) services have been shown to be a significant determinant of population 
health, effective cost-containment and promotion of equity objectives.1 Unger et al.2 showed that Original Research
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GPs  were  the  most  common  providers  of  chronic  disease 
primary care, with over 90% of respondents reporting that 
they had visited a GP at least once in the past 12 months. 
Utilisation data on GPs’ services by medical scheme members 
report an average of three annual visits. Barnes, Jonsson and 
Klim3 report that Canadian patients visit doctors more often 
(4.9 annual GP visits) than Australian patients (2.3–3.6 visits), 
whilst Harris4 contends that on average Australians visit a 
GP five times per year. 
Key focus 
Medical scheme members are entitled to certain benefits that 
the schemes have to cover in full. These are called Prescribed 
Minimum Benefits (PMBs), and the PMB Chronic Disease 
List is a list of conditions which all medical schemes need 
to cover on all the plans they offer to their members. This 
cover includes funding for diagnosis, treatment and ongoing 
care for the listed conditions.5 However, from a member’s 
perspective  there  is  still  a  lack  of  understanding  of  what 
these benefits actually entail. A recent survey by Old Mutual 
Consulting Actuaries6 revealed that 85% of members do not 
understand their PMB entitlements, or where to access PMBs. 
However, a greater part of the problem is how these benefits 
are communicated to members. 
With regard to PMBs, schemes develop protocols to manage 
the use of benefits. Such protocols would specify, for example, 
types of tests, investigations and number of consultations.7 
Non-adherence  to  some  of  the  guidelines  can  have 
unintended consequences for the member, such as denial of 
benefits that a member is entitled to. Some schemes require 
members to register on disease management programmes 
prior to entitlement to such benefits. Consequences of not 
registering on such programmes are outlined in the medical 
schemes’  rules,  which  include  cases  where  an  unlimited 
benefit such as a PMB could be considered as a day-to-day 
benefit, thus unknowingly compromising member’s day-to-
day benefits, which are limited.
Literature  reviews  reveal  inconsistencies  or  variation  in 
how protocols or treatment guidelines for the PMB Chronic 
Disease  List  are  employed,  in  particular  with  regard  to 
number of consultations per annum, which is also a proxy 
for a benefit. In some guidelines patients who suffer from 
asthma and use chronic medication are entitled to a treatment 
plan that allows them two visits to a pulmonologist per year; 
two visits to a GP or physician; and tests such as peak-flow 
evaluations.8 For the purposes of this article we use annual 
average visits to the GP as a proxy for access to benefits, 
and  find  associations  with  select  chronic  diseases.  This 
seeks  to  advance  knowledge  on  GP  visits  for  monitoring 
and managing of chronic conditions and also as a tool to 
control costs. 
Background
Quantifying the impact of chronic disease on healthcare use 
can assist in estimating the return on investment of health 
promotion and other policies designed to prevent chronic 
diseases or better manage the costs associated with them.9 
Medical  schemes  employ  managed  care  programmes  to 
monitor  utilisation  and  control  costs;  these  programmes 
include  protocols  and  guidelines  that  also  prescribe  the 
number of visits to a GP. In The Netherlands a GP is responsible 
for  the  primary  care  of  an  average  of  2350  patients.10 
Literature reveals that Dutch GPs are the ‘gatekeepers’ of 
the healthcare system and provide most routine medical care 
and diagnostic evaluations for their patients. A patient can 
visit a specialist only after a GP referral.11 Other studies have 
also shown that delivering optimal health care for chronic 
illnesses  requires  health  systems  to  move  from  a  reactive 
approach to a proactive one.12 
Trends 
Long-term conditions are chronic illnesses that greatly affect 
people’s  lifestyles  and  require  ongoing  management  over 
years  or  decades.13  Chronic  conditions  such  as  diabetes, 
heart  disease  and  chronic  obstructive  pulmonary  disease 
affect over 17.5 million people in the United Kingdom (UK).14 
Approximately 75% – 85% of healthcare expenditure in the 
UK is related to chronic disease.15 Data show that 60% of 
people aged over 65 years have a chronic disease, and this is 
set to double in next 10 years. The literature further illustrate 
that in the UK 80% of GP consultations and more than half 
of hospital bed usage relates to a long-term condition.16,17,18 
Rationale
In  the  absence  of  complete  and  accurate  data,  measuring 
the effect of primary health service use and chronic disease 
management  programmes  becomes  difficult  to  assess. 
Prevalence  data  are  frequently  collected  through  surveys 
based  upon  self-reports  of  disease.18 Literature  shows  that 
people tend to under-report the presence of chronic disease; 
under-reporting of HIV and AIDS cases, for instance, is a 
common  problem  in  HIV  epidemiology  and  often  skews 
epidemiological projections.19 Other epidemiological studies 
have dealt with skewed or missing cases, as has the work 
of  Acuna  and  Rodriguez.20  It  is  known  that  missing  data 
can introduce bias into estimates derived from a statistical 
model.21  Missing  data  and  under-reporting  of  chronic 
conditions  are  also  key  challenges  in  the  medical  scheme 
environment, as reported in the Council for Medical Schemes 
report.22 
Another  example  is  HIV  reporting  in  the  mining  sector. 
A  mining  company  such  as  Implats  provides  treatment 
programmes  for  its  employees  through  its  own  medical 
facilities and in-house medical scheme; however, employees 
may choose to receive treatment through external medical 
facilities which do not report statistics to the company, or 
through  government-provided  systems.  As  a  result,  HIV 
and AIDS prevalence levels and other statistics related to the 
impact of the virus are not known with absolute certainty.23 
McLeod24 further states that the chronic diseases list covers 
the majority of people with chronic conditions, but warns 
that this would underestimate the burden of chronic disease 
in medical schemes.
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Enders25  reviewed  some  of  the  recent  methodological 
advances related to missing data, and provides an overview of 
two ‘modern’ analytical options: direct maximum likelihood   
estimation and multiple imputations. In the current article 
we  considered  multiple  imputations  for  dealing  with 
missing data. 
Objectives
The objective of this study was to examine the association 
between the prevalence of selected chronic diseases on health 
service  use,  in  particular  visits  to  GPs.  The  current  work 
seeks  to  identify  specific  chronic  diseases  that  may  need 
more attention and can be better managed sooner.
Contribution to field
This  study  investigated  factors  that  are  associated  with 
primary  healthcare  use,  in  particular  GPs’  services.  Some 
of  the  factors  included  most  prevalent  chronic  disease 
associated with visits to a GP. The findings of this study are 
essential in illustrating the significant role of primary care 
in managing care for patients, and also identifying chronic 
diseases that need more attention and monitoring and can be 
better managed sooner. The study seeks further to enhance 
understanding  of  some  of  the  best  practice  literature  in 
developing  and  determining  clinical  guidelines  associated 
with treating and managing chronic diseases. The study uses 
GP visits as a proxy for accessing chronic benefits. 
Ethical considerations
The current study was not a clinical trial study, and therefore 
did not directly involve treatment of patients. The data were 
assessed and only reported at consolidated level for privacy 
and confidentiality. 
Methods
Materials
The  data  used  were  sourced  from  the  annual  statutory 
return  submissions  which  schemes  submit  to  the  Office 
of  the  Registrar.  The  data  were  captured  on  the  annual 
statutory returns portal, then exported onto Microsoft Excel 
spreadsheets prior to the analysis phase.
Setting
Data  analysed  included  open  and  restricted  schemes  that 
were registered during the assessment period (data observed 
in  2009).  Inclusion  criteria  were  schemes  that  submitted 
complete data on the variables of interest.
Design
This was a retrospective cross-sectional study which included 
109 medical schemes that were registered and operational 
in 2009. A purposive sampling technique was used to select 
schemes based on specific characteristics: registered schemes 
for the period under review and completeness of data. The 
study was representative in terms of the number of schemes, 
beneficiaries  covered  and  number  of  benefit  options.  A 
sample of schemes represented 99.8% of the private-sector 
beneficiaries and 99.1% of registered benefit options in 2009.
Procedure
The total number of visits by beneficiaries of each scheme 
in  each  year  was  extracted  from  the  utilisation  section  of 
the annual statutory return data submissions. This was then 
weighted to account for the number of beneficiaries in each 
scheme. The average age of beneficiaries was computed at 
scheme level (Table 1). This was further organised into two 
strata, namely schemes with average member age of more 
than 35 years, and those with less than or equal to 35 years. 
This  cut-off  was  motivated  by  the  findings  of  a  study  by 
Aung,  Recehl  and  Odermatt,26  which  showed  that  being 
younger  than  35  years  was  a  main  barrier  to  accessing 
primary healthcare services. A study by Fuster, Voute, Hunn 
and Smith27 revealed that 41% of all deaths in South Africa 
were due to heart disease, and this occurred in people 35–
64 years of age. Furthermore, actuarial projections in South 
Africa suggest that chronic diseases are expected to increase, 
with HIVand AIDS ravaging those aged 18–35 years.28 The 
report further highlights the alarming fact that South Africa is 
already losing a significant amount of people in the workforce 
age group of 35–64 years because of cardiovascular disease.28
Other covariates considered for predicting average number 
of visits to a GP included a select list of chronic diseases 
The following 10 selected chronic conditions are those most 
prevalent with the medical schemes:23,29 
•	 Hypertention
•	 Hyperlipideamia
•	 Asthma
•	 Coronary artery disease
•	 HIV
•	 Hypothyroidism
•	 Epilepsy
•	 Diabetes mellitus type 1
•	 Diabetes mellitus type 2
•	 Cardiac failure.
Chronic disease permeates several aspects of health service 
utilisation,  and  can  be  implicated  in  many  diagnoses; 
therefore,  all  services  for  all  relevant  ICD-10  diagnostic 
codes  were  included.  Prevalence  of  chronic  disease  was 
defined by counting every beneficiary who has any of the 
selected chronic conditions; where beneficiaries had multiple 
conditions, each condition was counted separately. 
TABLE 1: Covariates under investigation: demographic characteristics. 
Medical schemes  Average number of visits to a GP per beneficiary per annum
Scheme type
Open scheme Medical schemes that freely admit everyone
Restricted schemes Employer group schemes which only admit applicants 
belonging to a specific employment sector
Scheme size
Large More than 30 000 beneficiaries
Medium More than 6000 principal members but not more than 
30 000 beneficiaries 
Small All schemes with less that 6000 principal members
Scheme age strata 
> 35 vs. ≤ 35 Average age of beneficiaries at scheme level was stratified by 
> 35 and ≤35 yearsOriginal Research
doi:10.4102/phcfm.v4i1.419 http://www.phcfm.org
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Statistical analysis 
Descriptive  statistics  were  calculated  to  characterise  the 
distribution  of  chronic  disease  in  the  sample  population. 
The  median  imputation  method  was  employed  to  deal 
with missing and unreported cases. This is one of the most 
frequently used methods, especially when the distribution of 
values of a given feature is skewed.30 According to Durrant,31 
the  imputation  method  reduces  non-response  bias  due  to 
missing  values.  The  median  imputation  method  consists 
of replacing the missing data for a given feature (attribute) 
with the median of all known values of that attribute in the 
class where an instance is missing. The capping or flooring 
approach was employed to deal with the outliers.32
Multivariate  logistic  regression  analysis  methods  were 
employed to assess the effects of the prevalence of chronic 
illnesses on visits to a GP. Average annual GP visits were 
used to enhance ability of the statistical models to estimate 
the variance in utilisation attributable to chronic disease.33 
The outcome variable was stratified into two groups to form 
a dichotomous outcome: schemes with average annual visits 
to a GP > 3 and those with visits ≤ 3. 
Continuous  measurement  of  variables  such  as  prevalence 
of selected conditions such as HIV, asthma, hypertension, 
diabetes types 1 and 2, epilepsy, hyperlipidaemia, coronary 
artery  disease,  hypothyroidism  and  cardiac  failure  were 
included as covariates in the multivariate logistic regression 
model. The average age of beneficiaries in schemes, scheme 
type,  and  scheme  size  were  also  considered  as  covariates 
in  the  model.  We  conducted  all  the  analysis  using  SAS 
software, version 9.2 (SAS Institute Inc., Cary, NC). Statistical 
significance tests were conducted at α = 0.05 level (p < 0.05); 
odds ratio (OR) and the 95% confidence intervals (CIs) were 
also reported. 
Results
Participant characteristics
The sample of schemes analysed represented 99.8% of the 
private-sector beneficiaries and 99.1% of registered benefit 
options for the 2009 data. The median number of visits to 
a GP in 2009 was 3.2 (IQR = 2.4–3.7), and the median of 
the average age of beneficiaries was 32.91 years (IQR 
= 30.1–36.6) (Table 2). The median prevalence rate per 1000 
beneficiaries for hypertension was 109.5 (IQR = 82.8–159.0), 
followed by hyperlipidaemia at 52.9 (IQR = 29.9–78.9). The 
median prevalence rate for asthma was 27.9 (IQR = 20.3
–37.5), hypothyroidism 19.8 (IQR = 11.7–31.5) and cardiac 
failure  4.2  (IQR  =  1.4  –7.1)  per  1000  beneficiaries.  The 
prevalence  of  beneficiaries  with  type  2  diabetes  mellitus 
was  30.1  (IQR  =  20.7–38.3)  per  1000  beneficiaries.  The 
prevalence of select chronic diseases per 1000 beneficiaries 
for the medical schemes considered in the current study. 
The average number of GP visits for restricted schemes was 
slightly higher than in open schemes (3.3 compared to 2.9 
visits [Table 2]). 
The  prevalence  of  chronic  disease  in  open  schemes  was 
slightly higher than in restricted schemes, except for HIV 
cases (7.8 compared to 6.4/1000 beneficiaries) and cardiac 
failure  (7.4  compared  to  5.0/1000  beneficiaries).  The 
difference  in  average  expenditure  on  GP  visits  between 
open and restricted schemes was not significant, at R52.70 
compared R67.60 per beneficiary per month. Overall, total 
benefits paid to providers were higher in open schemes than 
in restricted schemes.
Results revealed that the prevalence rate of cardiac failure 
in the older profiled schemes was nearly twice that in the 
older  group  (Table  3).  The  prevalence  of  coronary  artery 
disease in the older profiled schemes was nearly three times 
that in the younger profiled schemes. Prevalence rates for 
hyperlipidaemia, hypertension, hypothyroidism and type 2 
diabetes were twice as high for the older profiled schemes as 
for the younger profiled schemes. Average expenditure on 
GPs was not significantly different between the younger and 
the older profiled schemes, at R58.70 compared to R49.52 per 
beneficiary per month. 
TABLE 2:  Prevalence of select chronic diseases per 1000 beneficiaries by scheme type.
Variables Total (N = 109) Open (N = 33) Restricted (N = 76) Median   IQR  p-value
GP visits per annum 3 2.9 3.3 3.2 2.4−3.7 0.065
Asthma 26.7 28.9 23.5 27.9 20.3−37.5 0.09
Cardiac failure 6 5 7.4 4.2 1.4−7.1 0.332
Coronary artery disease 14.9 16.9 11.8 14.6 7.7−23.3 0.958
Type 1 diabetes 6.5 7.3 5.2 4.4 2.8−7.9 0.774
Type 2 diabetes 28.5 29.2 27.5 30.1 20.7−38.3 0.966
Epilepsy 7.1 7.8 6 7.2 5.2−9.7 0.63
HIV 7 6.4 7.8 6 0.2−12.9 0.719
Hyperlipidaemia 48.4 52.8 42 52.9 29.9−78.9 0.222
Hypertension 107.7 113.3 99.3 109.5 82.8−159.0 0.887
Hypothyroidism 18 19.1 16.2 19.8 11.7−31.5 0.34
Benefits paid per beneficiary per month (ZAR)
GPs 58.7 52.7 67.6 59.8 44.7−70.7 0.0002*
Total hospitals  293 315.9 258.9 313.2 251.5−392.2 < 0.0001*
Total benefits 790.1 827.3 734.8 860.2 707.8−1071.4 < 0.0001*
IQR, interquartile ranges.
*, p < 0.05; 1 ZAR/$ = 8.8Original Research
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Page 5 of 9
Hypertension was the most prevalent chronic disease, with 
117.17  compared  to  96.81  per  1000  beneficiaries  for  the 
stratum, and an average of 3+ visits compared to ≤3 visits 
for the stratum (Figure 1). The second most prevalent was 
hyperlipidaemia  with  60.24  compared  to  35.54  per  1000 
beneficiaries and 3+ visits compared to ≤3 visits. Asthma 
and diabetes type 2 were the third and fourth most prevalent 
chronic diseases in the data presented. 
Missing  and  non-reported  cases  were  identified  and  cross-
validated  by  a  comparison  analysis  of  the  conditions, 
looking at previous years’ data on the same schemes and 
also  triangulating  with  the  Risk  Equalisation  Fund  data 
submissions.  Risk-equalisation  is  a  mechanism  that  was 
proposed  for  achieving  equity  and  efficiency  in  regulated 
private  health  insurance  markets.  (The  Risk  Equalisation 
Fund has been operating in shadow mode since 2005, with 
data being collected from schemes but no money changing 
hands; it was scheduled to be implemented 2012–2013.) All 
of the adjusted cases were denoted with the suffix ‘2’, and 
these were compared to the reported data. The median in 
each plot was denoted with the prefix ‘M’ (Figure 2).
A measurable deviation between reported cases and adjusted 
cases  was  noted.  The  most  prevalent  non-responses  were 
cases  of  HIV,  cardiac  failure  and  hypothyroidism.  In  the 
first model, denoted by ML1, we employed a rule of thumb 
where all non-reported cases of less than five were replaced 
by the median. The second model, denoted ML2, is where 
all reported cases less than the 50th percentile for chronic 
prevalence were replaced by the median. In the third and last 
model, denoted ML3, all reported cases smaller than the 10th 
percentile were replaced by the median. Capping for all three 
models was at the 90th percentile. Comparative statistics on 
the results of the three fitted models are discussed in the 
next section.
Modelling prevalence of chronic diseases associated with 
primary healthcare visits
All  three  criteria  for  assessing  goodness  of  fit  suggested 
that ML3 was a better fit for modelling GP visits, and the 
test statistics confirming this are Chi-square = 26.14, p = 0.0249 
(Table  4).  Results  obtained  from  fitting  this  model  are 
presented  (Table 5). Regression results for ML3 revealed that 
scheme size, asthma, type 2 diabetes, hyperlipidaemia and 
hypertension were significantly associated with GP visits.
TABLE 3: Age stratum of beneficiaries in schemes.
Beneficiaries <35 years 
(N = 39)
≥ 35 years 
(N = 70)
p-value
Average number of GP visits per 
year
3.2 2.5 0.6
Prevalence of select chronic diseases per 1000 beneficiaries
Asthma 25.7 31.1 0.0*
Cardiac failure 5.3 8.6 <0.0001*
Coronary artery disease 11.3 30.1 0.0*
Type 1 diabetes 6.3 7.4 0.1
Type 2 diabetes 25.2 42.8 <0.0001*
Epilepsy 6.4 9.7 <0.0001*
HIV 7.2 6.1 0.3
Hyperlipidaemia 38.4 91.3 <0.0001*
Hypertension 89.9 184 <0.0001*
Hypothyroidism 13.7 36.1 <0.0001*
Benefits paid per beneficiary per month (ZAR)
GPs 58.7 49.5 0.3
Total hospitals 293 397.3 <0.0001*
Total benefits 790.1 995.8 <0.0001*
*, p < 0.05; 1 ZAR/$ = 8.8
FIGURE 1: Prevalence rates of selected chronic diseases by General Practitioner visit stratum at scheme level.
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FIGURE 2: Graphic representation of the selected chronic diseases (median vs. reported vs. adjusted prevalence rates).
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Results indicate that average age of beneficiaries at scheme 
level,  scheme  type,  and  prevalence  of  cardiac  failure, 
coronary artery disease, type 1 diabetes, epilepsy, HIV and 
hyperlipidaemia  are  not  significant  in  terms  of  average 
number of GP visits (Table 5). They further illustrated that 
those on small schemes were likely to have more than three 
visits compared to those on medium schemes (OR = 0.16; 
95% CI = 0.039–0.661); otherwise there were no significant 
differences between small and large schemes. 
The  data  further  showed  that  prevalence  of  asthma  was 
significantly associated with GP visits (OR = 1.081; 95% 
CI = 1.008–1.159). Thus, asthma prevalence rates were likely 
to be associated with more than three GP visits, similar to the 
prevalence of type 2 diabetes, with OR = 1.087; 95% CI = 1.027–
1.152. The prevalence of hyperlipidaemia (OR = 0.92; 95% 
CI = 0.875–1.644) was more likely to be associated with less 
than three GP visits. Lastly, prevalence rates for hypertension 
were likely to be associated with more than three GP visits 
per year (OR = 1.132; 95% CI = 1.017–1.26).
Discussion
Chronic  illnesses  greatly  impact  on  the  patients’  way  of 
life  and  require  ongoing  monitoring  and  management. 
Proactively  managing  such  illnesses  through  educational 
and continuous monitoring methods could certainly improve 
the health status of the country. A survey by Seghieri et al.34 
confirmed that informing patients about their care and how 
to manage condition-related symptoms may lead to more 
effective chronic disease management and improved health 
status. Informing patients about their care should incorporate 
effectively communicating to patients or beneficiaries as to 
their benefit entitlement, particularly PMBs. 
The Medical Schemes Act35 requires that limitation on disease 
coverage  be  developed  on  the  basis  of  evidence-based 
medicine. For instance, some schemes specify in their rules 
that  patients  who  suffer  from  asthma  and  use  chronic 
medication are entitled to a treatment plan that allows them 
two visits to a pulmonologist per year; two visits to a GP or 
physician; and tests such as peak-flow evaluations. All these 
data should be communicated to the member, as should the 
implication of not registering on a scheme’s chronic disease 
management programme as per scheme rules, and how this 
could affect their day-to-day benefits. 
The  average  number  of  GP  visits  in  the  private  medical 
schemes data in 2009 was three.36 This is slightly lower than 
the Canadian average (Canadian patients visit doctors more 
often than Australian patients, making 4.9 GP visits annually 
compared to 2.3–3.6 in Australia3); however, Harris4 states 
that on average Australians visit a GP five times per year. 
According to an HLC Financial Services publication, one of 
the biggest open schemes in South Africa covers four GP 
consultations per year for each approved chronic disease.37 
Our  study  showed  that  the  prevalence  of  asthma  was 
significantly associated with more than the average of three 
annual visits to a GP (OR = 1.081; 95% CI = 1.008–1.159; p = 
0.0291). These results are consistent with the data analysed 
by Barnes38, where it was recommended that patients with 
mild asthma required three to five visits to their GP annually. 
Their study further illustrated that individuals with moderate 
asthma appeared to contribute more to the burden of asthma 
care than those with severe asthma.
Our  study  also  revealed  a  significant  association  between 
prevalence of type 2 diabetes and the average number of GP 
visits per year (OR = 1.087; 95% CI = 1.027–1.152, p = 0.0041). 
Thus, beneficiaries with type 2 diabetes were likely to make 
more than three visits to a GP. These results are consistent 
with the literature; for instance, a study by Johnson, Rabi, 
Edwards and Balko39 showed that adults with diabetes made 
more than nine GP visits on average, whilst those with no 
diabetes made just over five. Another study by Bottomley 
and the T2ARDIS Steering Committee40 showed that patients 
with type 2 diabetes visited their GP on average five times a 
year, and the GP visited them at home once every two years. 
Rutten,  Van  Eijk,  De  Nobel,  Beek  and  Van  der  Helden41 
studied the relationship between the number of clinic visits 
for diabetes patients and changes in blood glucose control; 
their study illustrated that at the frequency of two visits per 
year, HbAl decreased in 31% of patients, with three or four 
visits in 35%, and with five or more in 79% of patients (p < 0.005). 
Our  study  also  revealed  a  significant  association  between 
hyperlipidaemia  and  primary  healthcare  use.  This  is 
consistent with the literature; Eaton et al.42 state that family 
physicians have potential to make a major impact on reducing 
the  burden  of  cardiovascular  disease  through  the  optimal 
assessment and management of hyperlipidemia. Their study 
also found that the frequency of primary care visits seemed 
to  be  fairly  uniform  for  both  well-controlled  (average  2.2 
TABLE 4: Summary of fitting predictors of primary health care use.
Criterion ML1 ML2 ML3
-2 Llog likelihood 106.366 111.401 99.39
AIC (smaller is better)  136.366 141.401 129.39
SC (smaller is better)  176.736 181.771 169.76
AIC, Akaike Information Criterion; SC, Schwarz Criterion are criterion for the measure of the 
relative goodness of fit of a statistical model; ML1, Mixed Linear Model 1; ML2,Mixed Linear 
Model 2; ML3, Mixed Linear Model 3.
TABLE 5: Multivariate logistic regression results for prediction.
Covariates OR 95% LCI 95% UCI p - value
Scheme type  
(restricted vs. open)
2.758 0.759 10.02 0.1232
Age stratum (> 35 vs. <35 ) 2.656 0.563 12.54 0.2174
Scheme size (large vs. small) 0.333 0.093 1.19 0.0907*
Scheme size (medium vs. small) 0.161 0.039 0.661 0.0343**
Asthma 1.081 1.008 1.159 0.0291**
Cardiac failure 1.108 0.893 1.375 0.3522
Coronary artery disease 0.947 0.862 1.04 0.2537
Type 1 diabetes 0.941 0.849 1.044 0.2543
Type 2 diabetes 1.087 1.027 1.152 0.0041**
Epilepsy 1.199 0.875 1.644 0.2597
HIV 1.049 0.967 1.138 0.252
Hyperlipidaemia 0.92 0.87 0.973 0.0037**
Hypertension 1.132 1.017 1.26 0.0233**
Hypothyroidism 0.997 0.975 1.019 0.7605
* p < 0.1; ** p < 0.05, OR, odds ratio; LCI, lower confidence interval; UCI, upper confidence 
interval; ≤3 visits versus 3+ visits.Original Research
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visits per year) and uncontrolled hyperlipidaemic (4.2 visits 
per year) patients. Lastly, our study revealed a significant 
association between hypertension and GP visits (OR = 1.132; 
95% CI = 1.017–1.26). 
Limitations of the study
One  of  the  limitations  of  the  study  is  that  risk  factors 
associated with chronic diseases were not explored. These 
include tobacco use, obesity or diet, hypercholesterolaemia, 
alcohol  abuse,  sedentary  lifestyle  and  certain  infectious 
diseases.43 Another limitation is that we did not risk-adjust 
the reported chronic prevalence for particular age groups, 
genders  and  ethnic  groups.  Al-Windi44 has  shown  that  a 
higher  proportion  of  females  than  males  had  one  to  five 
or more than five GP consultations per year. According to 
Polisson,45 demand  for  GP  visits  is  most  likely  driven  by 
health status and, for women, childbirth. 
It is also known that some chronic diseases are more prevalent 
in  certain  age  groups  and  genders;  hypothyroidism,  for 
example, is more common in older persons, especially women, 
principally  due  to  the  rising  incidence  and  prevalence  of 
auto-immune thyroiditis.46 A study by Pillar, Levy, Holcberg 
and  Sheiner47  showed  that  treated  hyperthyroidism  was 
not  associated  with  adverse  perinatal  outcome;  however, 
hyperthyroidism  was  found  to  be  an  independent  risk 
factor for caesarean delivery. Hyperthyroidism is common, 
affecting approximately 2% of women and 0.2% of men.48 
This further emphasises the importance of risk factors and 
risk adjustments to get a more holistic and better perspective 
of the results. 
Lastly,  data  was  analyses  were  at  scheme  level;  a  wide-
ranging  assessment  of  chronic  diseases  and  primary 
healthcare  benefits  at  benefit  option  level  could  certainly 
enhance the findings of the current study. However, it was 
illustrated during the Risk Equalisation Fund shadow period 
that even though benefit options differ in design, the CDL is 
about the same in each option.24 
Recommendations
Recommendations arising from the current study are that 
primary  healthcare  services  have  an  essential  role  in  the 
private  health  sector,  in  particular  in  managing  chronic 
disease.  The  results  obtained  and  this  study  adds  value 
to  managed  care  interventions  employed  by  schemes  in 
advocating  more  awareness,  educating  members  and 
continuous  monitoring  of  chronic  diseases.  This  proactive 
approach is vital for avoiding hospitalisations. 
Other  factors  were  not  taken  into  account  in  this  study, 
such  as  risk  factors  and  risk  adjustments;  however,  it  is 
recommended  that  patients  with  chronic  conditions  visit 
their GP frequently to identify specific problems that need 
more attention and can be better managed sooner. Some of 
the select chronic diseases need more attention than others; 
also, the severity of the condition impacts on number of visits 
to a GP. All these considerations should be taken into account 
when designing protocols and guidelines for provision of 
benefits. Furthermore, there is a need to review protocols 
employed by the schemes for provision of PMBs, to ensure 
that these are consistent with recent best practice and comply 
with the Medical Schemes Act, in particular Regulation 15.
Schemes  need  to  educate  members  on  their  benefit 
entitlement,  in  particular  chronic  benefits,  and  also  on 
the  consequences  of  not  registering  on  chronic  diseases 
programmes. Protocols and guidelines used as clinical risk 
measurement  tools  should  be  communicated  to  members; 
these should also outline the minimum standards required to 
control or manage the conditions. Such protocols and clinical 
risk measures should not compromise the health status of 
beneficiaries for cost-effectiveness.
Conclusion
The current study employed MI to account for missing data 
and outliers. This method allowed for a more complete set of 
data, to enhance the results of the multiple regression analysis 
model.  Using  these  statistical  methods  to  deal  with  the 
shortcomings of the data from medical schemes, we showed 
that scheme size, asthma, type 2 diabetes, hyperlipidaemia 
and hypertension were related to the annual number of GP 
visits. Some of the key chronic diseases considered in the 
current study were found not to have a significant link with 
number of GP visits, an indication that estimating the effect 
of chronic disease on health service use is complex. 
These  results  illustrate  the  minimum  number  of  visits 
required to manage select chronic diseases. The findings of 
the current study further enhance the role of primary health 
care  and  preventative  measures  employed  by  managed 
care entities as an effective tool to effectively avoid costly 
hospitalisation. 
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